2. Search Result
Search Result
Results for "

nicotinamide-adenine

" in MedChemExpress (MCE) Product Catalog:

37

Inhibitors & Agonists

5

Biochemical Assay Reagents

10

Peptides

4

Natural
Products

4

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B0445A
    NAD sodium
    Maximum Cited Publications
    27 Publications Verification

    β-DPN sodium; β-NAD sodium; β-nicotinamide adenine Dinucleotide sodium

    		 Endogenous Metabolite Metabolic Disease
    NAD (β-Nicotinamide Adenine Dinucleotide) sodium is an analogue of NAD. NAD sodium can be reduced to β-nicotinamide adenine dinucleotide (NADH) during coupling with reactions which oxidize organic substrates. NAD sodium can be converted to β-nicotinamide adenine dinucleotide (NADH) and passes to the inside of mitochondria that indirectly generates ATP .
    NAD sodium
  • HY-113432
    Nudifloramide

    2PY

    		 Endogenous Metabolite PARP Metabolic Disease
    Nudifloramide (2PY) is one of the end products of nicotinamide-adenine dinucleotide (NAD) degradation. Nudifloramide significantly inhibits poly(ADP-ribose) polymerase (PARP-1) activity in vitro .
    Nudifloramide
  • HY-B0445B
    α-NAD

    α-nicotinamide adenine Dinucleotide

    		 Others Others
    α-NAD (α-Nicotinamide Adenine Dinucleotide) serves as a substrate for renalase and functions as an analog of β-NAD, influencing the kinetics of NAD-dependent enzymes, while also playing a crucial role as a cofactor in mitochondrial oxidation-reduction reactions.
    α-NAD
  • HY-113432R
    Nudifloramide (Standard)

    2PY (Standard)

    		 Endogenous Metabolite PARP Metabolic Disease
    Nudifloramide (Standard) is the analytical standard of Nudifloramide. This product is intended for research and analytical applications. Nudifloramide (2PY) is one of the end products of nicotinamide-adenine dinucleotide (NAD) degradation. Nudifloramide significantly inhibits poly(ADP-ribose) polymerase (PARP-1) activity in vitro .
    Nudifloramide (Standard)
  • HY-113432S
    Nudifloramide-d3

    		Endogenous Metabolite PARP Metabolic Disease
    Nudifloramide-d3 (2PY-d3) is the deuterium labeled Nudifloramide. Nudifloramide (2PY) is one of the end products of nicotinamide-adenine dinucleotide (NAD) degradation. Nudifloramide significantly inhibits poly(ADP-ribose) polymerase (PARP-1) activity in vitro .
    Nudifloramide-d3
  • HY-E70410
    NAD Synthetase

    NAD+ Synthetase; nicotinamide adenine dinucleotide synthetase

    		 Endogenous Metabolite Neurological Disease Metabolic Disease Cancer
    NAD synthetase is responsible for the final step in the synthesis of nicotinamide adenine dinucleotide (NAD). The Km values for NAD, ATP, and ammonia of NAD synthetase from Escherichia coli are 200 μM, 11 μM, and 0.65 μM, respectively, while the Km values for NAD, ATP, and ammonia of NAD synthetase from yeast are 170 μM, 190 μM, and 64 μM, respectively. NAD synthetase can be used for enzymatic assays to determine ATP, ammonia, urea, or creatinine, and is also suitable for enzymatic cycling methods. Additionally, NAD synthetase holds potential for research into metabolic diseases, cancer, aging, and neurodegenerative diseases .
    NAD Synthetase
  • HY-W250154
    β-Nicotinamide adenine dinucleotide reduced dipotassium

    		Endogenous Metabolite Metabolic Disease
    β-Nicotinamide adenine dinucleotide reduced dipotassium is an orally active reduced coenzyme. β-Nicotinamide adenine dinucleotide reduced dipotassium is a donor of ADP-ribose units in ADP-ribosylaton reactions and a precursor of cyclic ADP-ribose. β-Nicotinamide adenine dinucleotide reduced dipotassium plays a role as a regenerative electron donor in cellular energy metabolism, including glycolysis, β-oxidation and the tricarboxylic acid (TCA) cycle .
    β-Nicotinamide adenine dinucleotide reduced dipotassium
  • HY-W250163
    NAD+ lithium

    β-DPN lithium; β-NAD lithium; β-nicotinamide adenine Dinucleotide lithium

    		 Biochemical Assay Reagents Metabolic Disease
    NAD+ lithium (β-DPN lithium) is a lithium salt of nicotinamide adenine dinucleotide. NAD+ is a coenzyme in the REDOX reaction. NAD+ can directly or indirectly affect several key cellular functions, including metabolic pathways, DNA repair, chromatin remodeling, cell aging, and immune cell function .
    NAD+ lithium
  • HY-137672A
    2',3'-Cyclic NADP disodium

    2',3'-cNADP+; β-nicotinamide adenine dinucleotide-2',3'-cyclic phosphate

    		 Phosphodiesterase (PDE) Calcium Channel Neurological Disease
    2',3'-Cyclic NADP disodium (2',3'-cNADP+; β-Nicotinamide adenine dinucleotide-2',3'-cyclic phosphate) is a substrate for 2',3'-cyclic nucleotide 3'-phosphodiesterase (CNP), an enzyme abundant in myelin. It has been used in a coupled enzyme assay to quantify CNP activity. 2',3'-Cyclic NADP disodium (5 μM) increases calcium overload-induced calcium release and prevents calcium-induced swelling in rat brain mitochondria.
    2',3'-Cyclic NADP disodium
  • HY-E70406
    Cholesterol Dehydrogenase, Nocardia sp.

    CHDH-5

    		 Endogenous Metabolite Others
    Cholesterol Dehydrogenase, Nocardia sp. is an enzyme that uses nicotinamide adenine dinucleotide/nicotinamide adenine dinucleotide phosphate (NAD(P)) as its cofactor in oxidizing cholesterol to form cholest-4-en-3-one. This enzyme oxidizes the hydroxyl group at the 3 position of the sterol ring to form a ketone.
    Cholesterol Dehydrogenase, Nocardia sp.
  • HY-131485
    3-Acetylpyridine adenine dinucleotide, 90%

    3-APAD, 90%; 3-Acetylpyridine NAD, 90%

    		 Lactate Dehydrogenase Metabolic Disease
    3-Acetylpyridine adenine dinucleotide, 90% is an analog of nicotinamide adenine dinucleotide (NAD). 33-Acetylpyridine adenine dinucleotide, 90% collaboratively inhibits Lactate Dehydrogenase (LDH) with bisulfite .
    3-Acetylpyridine adenine dinucleotide, 90%
  • HY-P2804
    GAPDH, rabbit muscle

    GADPH; G3PDH; Glyceraldehyde phosphate dehydrogenase

    		 Endogenous Metabolite Others
    Glyceraldehyde phosphate dehydrogenase (EC 1.2.1.12) is the target of anti-thymocyte and anti-apoptotic agents. Glyceraldehyde phosphate dehydrogenase catalyzes the chain oxidation of reduced nicotinamide adenine dinucleotide by perhydroxyl radicals .
    GAPDH, rabbit muscle
  • HY-131485A
    3-Acetylpyridine adenine dinucleotide, 95%

    3-APAD, 95%; 3-Acetylpyridine NAD, 95%

    		 Lactate Dehydrogenase Metabolic Disease
    3-Acetylpyridine adenine dinucleotide, 95% (3-APAD, 95%)is an analog of nicotinamide adenine dinucleotide (NAD). 33-Acetylpyridine adenine dinucleotide, 95% collaboratively inhibits Lactate Dehydrogenase (LDH) with bisulfite .
    3-Acetylpyridine adenine dinucleotide, 95%
  • HY-157421
    Nampt activator-4

    		NAMPT Others
    Nampt activator-4 is a positive allosteric modulator (N-PAM) of nicotinamide phosphoribosyltransferase (NAMPT) with an EC50 of 0.058 μM. Nampt activator-4 can enhance the nicotinamide adenine dinucleotide (NAD +) in cells .
    Nampt activator-4
  • HY-B0445
    NAD+
    Maximum Cited Publications
    27 Publications Verification

    β-DPN; β-NAD; β-nicotinamide adenine Dinucleotide

    		 Endogenous Metabolite Metabolic Disease
    NAD+ is a coenzyme composed of ribosylnicotinamide 5'-diphosphate coupled to adenosine 5'-phosphate by pyrophosphate linkage.
    NAD+
  • HY-156424
    NOX2-IN-1

    		NADPH Oxidase Inflammation/Immunology
    NOX2-IN-1 (compound 10) is an inhibitor of nicotinamide adenine dinucleotide phosphate oxidase isoform 2 (NOX2). NOX2-IN-1 targets the p47phox p22phox protein protein interaction with favorable binding affinities and cellular activities .
    NOX2-IN-1
  • HY-134355
    ADPRP

    		Others Others
    ADPRP is an intranuclear enzyme whose main activity is to use NAD+ (nicotinamide adenine dinucleotide) as a substrate to add ADP-ribose units to chromatin-bound proteins, including the ADPRP enzyme itself. This process, called poly(ADP-ribosylation), is a post-translational modification that regulates the interaction between DNA and nuclear proteins .
    ADPRP
  • HY-100973A
    Adenosine 5′-diphosphoribose sodium
    4 Publications Verification

    ADP ribose sodium

    		 TRP Channel Autophagy Metabolic Disease Endocrinology Cancer
    Adenosine 5′-diphosphoribose sodium (ADP ribose sodium) is a nicotinamide adenine nucleotide (NAD +) metabolite. Adenosine 5′-diphosphoribose sodium is the most potent and primary intracellular Ca 2+-permeable cation TRPM2 channel activator. Adenosine 5′-diphosphoribose sodium also can enhance autophagy .
    Adenosine 5′-diphosphoribose sodium
  • HY-134280
    8-Br-NHD+

    nicotinamide 8-Br-hypoxanthine dinucleotide

    		 Drug Derivative Others
    8-Br-NHD+ (Nicotinamide 8-Br-hypoxanthine dinucleotide) is a derivative of NAD+ (nicotinamide adenine dinucleotide) that acts as a potential substrate, competitive inhibitor or modulator of enzymes that interact with β-NAD+. 8-Br-NHD+ can be used to synthesize a cyclic ADP nucleotide (cADPR) analog .
    8-Br-NHD+
  • HY-125863C
    Glucose-6-phosphate dehydrogenase, Bacillus sp.

    G6PD, Bacillus sp.

    		 Endogenous Metabolite Others
    Glucose-6-phosphate dehydrogenase, Bacillus sp. catalyzes the conversion of glucose-6-phosphate into 6-phosphogluconolactone, and produces reduced nicotinamide adenine dinucleotide phosphate (NADPH) and ribose-5-phosphate in this process. Glucose-6-phosphate dehydrogenase, Bacillus sp. can be used in research about diabetic complications .
    Glucose-6-phosphate dehydrogenase, Bacillus sp.
  • HY-14374
    GPP78
    1 Publications Verification

    CAY10618

    		 NAMPT Autophagy Inflammation/Immunology Cancer
    GPP78 (CAY10618) is a potent Nampt inhibitor with an IC50 of 3.0 nM for nicotinamide adenine dinucleotide (NAD) depletion. GPP78 is cytotoxic to neuroblastoma cell line SH-SY5Y cells with an IC50 of 3.8 nM by inducing autophagy. GPP78 has anti-cancer and anti-inflammatory effects .
    GPP78
  • HY-150508
    MK-0159

    		CD38 Cardiovascular Disease Metabolic Disease Inflammation/Immunology
    MK-0159 is an orally active, potent and selective CD38 inhibitor, with IC50 values of 22, 3, and 70 nM for human, mouse and rat CD38, respectively. MK-0159 also shows good microsomal stability for human and rodent liver microsomes. MK-0159 increases NAD + (nicotinamide adenine dinucleotide) and reduces ADPR (adenosine diphosphate ribose) in whole blood and heart .
    MK-0159
  • HY-151936
    LmNADK1-IN-1

    		Bacterial Infection
    LmNADK1-IN-1 (compound MC1) is an inhibitor of nicotinamide adenine dinucleotide kinases (NADK1) from L. monocytogenes with a Ki value of 54 nM. LmNADK1-IN-1 can be used for the research of bacterial infection . LmNADK1-IN-1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    LmNADK1-IN-1
  • HY-100973AR
    Adenosine 5′-diphosphoribose sodium (Standard)

    ADP ribose sodium (Standard)

    		 Reference Standards TRP Channel Autophagy Metabolic Disease Endocrinology Cancer
    Adenosine 5′-diphosphoribose (sodium) (Standard) is the analytical standard of Adenosine 5′-diphosphoribose (sodium). This product is intended for research and analytical applications. Adenosine 5′-diphosphoribose sodium (ADP ribose sodium) is a nicotinamide adenine nucleotide (NAD+) metabolite. Adenosine 5′-diphosphoribose sodium is the most potent and primary intracellular Ca2+-permeable cation TRPM2 channel activator. Adenosine 5′-diphosphoribose sodium also can enhance autophagy .
    Adenosine 5′-diphosphoribose sodium (Standard)
  • HY-172919
    PDEδ/NAMPT IN-1

    		Phosphodiesterase (PDE) NAMPT Apoptosis Cancer
    PDEδ/NAMPT IN-1 (Compound 17d) is a dual inhibitor targeting phosphodiesterase 6 (PDE6) (KD=0.410 nM) and nicotinamide phosphoribosyl transferase (NAMPT) (IC50=2.21 nM). PDEδ/NAMPT IN-1 blocks KRAS-related signal transduction and interferes with the synthesis of nicotinamide adenine dinucleotide (NAD +), inducing apoptosis in KRAS mutant pancreatic cancer cells. PDEδ/NAMPT IN-1 is promising for research of KRAS mutant pancreatic cancer .
    PDEδ/NAMPT IN-1
  • HY-W654288
    NAD+-d4

    β-DPN-d4; β-NAD-d4; β-nicotinamide adenine Dinucleotide-d4

    		 Isotope-Labeled Compounds Others
    NAD+-d4 is the deuterium-labeled NAD+ (HY-B0445). NAD+-d4 is a coenzyme composed of ribosylnicotinamide 5'-diphosphate coupled to adenosine 5'-phosphate by pyrophosphate linkage.
    NAD+-d4
  • HY-B0445S1
    NAD+-13C5

    β-DPN-13C5; β-NAD-13C5; β-nicotinamide adenine Dinucleotide-13C5

    		 Endogenous Metabolite Metabolic Disease
    NAD+- 13C5-1 is the 13C labeled NAD+ . NAD+ is a coenzyme composed of ribosylnicotinamide 5'-diphosphate coupled to adenosine 5'-phosphate by pyrophosphate linkage.
    NAD+-13C5
  • HY-P4154
    Bevonescein

    ALM-488

    		 Fluorescent Dye Neurological Disease Cancer
    Bevonescein (ALM-488) is a novel, intravenously-administrated fluorescein-conjugated peptide that binds nerve-associated connective tissue, labels peripheral nerves under real-time fluorescence imaging (FL) in living mice and human ex vivo nerve tissue. Bevonescein is a peptide-linked tracer which fluorescently labeled both intact and degenerated nerves .
    Bevonescein
  • HY-B0445S
    NAD+-13C5 ammonium

    β-DPN-13C5 ammonium; β-NAD-13C5 ammonium; β-nicotinamide adenine Dinucleotide-13C5 ammonium

    		 Isotope-Labeled Compounds Metabolic Disease
    NAD+-13C5 (ammonium) is the 13C labled NAD+ (HY-B0445), with an ammonium .
    NAD+-13C5 ammonium
  • HY-P1103
    CTCE-9908
    1 Publications Verification

    		 CXCR Cancer
    CTCE-9908 is a potent and selective CXCR4 antagonist. CTCE-9908 induces mitotic catastrophe, cytotoxicity and inhibits migration in CXCR4-expressing ovarian cancer cells .
    CTCE-9908
  • HY-P1103A
    CTCE-9908 TFA

    		CXCR Cancer
    CTCE-9908 TFA is a potent and selective CXCR4 antagonist. CTCE-9908 TFA induces mitotic catastrophe, cytotoxicity and inhibits migration in CXCR4-expressing ovarian cancer cells .
    CTCE-9908 TFA
  • HY-P2231A
    Cotadutide acetate
    1 Publications Verification

    MEDI0382 acetate

    		 GCGR Metabolic Disease
    Cotadutide (MEDI0382) acetate is a potent dual agonist of glucagon-like peptide-1 (GLP-1) and GCGR with EC50 values of 6.9 pM and 10.2 pM, respectively. Cotadutide acetate exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide acetate can be used in the research of obesity and type 2 diabetes (T2D) .
    Cotadutide acetate
  • HY-P10026
    Nisotirostide

    LY-3457263

    		 Neuropeptide Y Receptor Metabolic Disease
    Nisotirotide (LY-3457263) is a subcutaneous injectable NPY2 receptor agonist. By mimicking peptide YY (PYY), Nisotirotide inhibits appetite and can be used in the research of diseases such as obesity and diabetes .
    Nisotirostide
  • HY-P4757
    N1-Glutathionyl-spermidine disulfide

    		Parasite Others
    N1-Glutathionyl-spermidine disulfide is a substrate of trypanothione reductase .
    N1-Glutathionyl-spermidine disulfide
  • HY-P2231
    Cotadutide
    1 Publications Verification

    MEDI0382

    		 GCGR Metabolic Disease
    Cotadutide (MEDI0382) is a potent dual agonist of glucagon-like peptide-1 (GLP-1) and GCGR with EC50 values of 6.9 pM and 10.2 pM, respectively. Cotadutide exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide can be used in the research of obesity and type 2 diabetes (T2D) .
    Cotadutide
  • HY-P1321
    GR231118

    1229U91; GW1229

    		 Neuropeptide Y Receptor Neurological Disease
    GR231118, an analogue of the C-terminus of neuropeptide Y, is a potent , competitive and relative seletive antagonist at human neuropeptide Y Y receptor with a pKi of 10.4. GR231118 a potent agonist at the human neuropeptide Y Y4 receptor (pEC50=8.6; pKi=9.6) and a weak agonist at the human and rat neuropeptide YY2 and Y5 receptors. GR231118 also has high affinity for the mouse neuropeptide Y Y6 receptor (pKi= 8.8) .
    GR231118
  • HY-P1321A
    GR231118 TFA

    1229U91 TFA; GW1229 TFA

    		 Neuropeptide Y Receptor Neurological Disease
    GR231118 TFA, an analogue of the C-terminus of neuropeptide Y, is a potent , competitive and relative seletive antagonist at human neuropeptide YY receptor with a pKi of 10.4. GR231118 a potent agonist at the human neuropeptide YY4 receptor (pEC50=8.6; pKi=9.6) and a weak agonist at the human and rat neuropeptide Y Y2 and Y5 receptors. GR231118 also has high affinity for the mouse neuropeptide YY6 receptor (pKi= 8.8) .
    GR231118 TFA

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: